Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EVAGELOS COSKINAS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1437382314
CMS profile
201763
Location
RIVERSIDE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$497.65

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $497.65 10

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Teva Pharmaceuticals USA, Inc. $163.26 4
LivaNova USA, Inc. $124.93 1
E.R. Squibb & Sons, L.L.C. $118.79 1
Alkermes, Inc. $42.09 2
Indivior Inc. $27.61 1
Neurocrine Biosciences, Inc. $20.97 1

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EVAGELOS COSKINAS

NPI 1437382314 · CMS profile ID 201763

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

RIVERSIDE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437382314?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437382314?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437382314?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1437382314?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $497.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $118.7912/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101849410 CMS
Teva Pharmaceuticals USA, Inc. $126.2510/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151646295 CMS
Teva Pharmaceuticals USA, Inc. $8.2808/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151646291 CMS
Indivior Inc. $27.6105/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144526262 CMS
Teva Pharmaceuticals USA, Inc. $9.1504/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151646265 CMS
Alkermes, Inc. $20.4804/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120483926 CMS
Neurocrine Biosciences, Inc. $20.9704/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150854746 CMS
Teva Pharmaceuticals USA, Inc. $19.5803/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151646243 CMS
Alkermes, Inc. $21.6103/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120483924 CMS
LivaNova USA, Inc. $124.9303/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152799123 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $92.48 5
PY2020 $28.27 1
PY2021 $85.12 1
PY2022 $87.50 1
PY2023 $75.07 3
PY2024 $497.65 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,435,713.44 192
PY2024 Principal investigator $1,112,891.48 274
PY2023 Principal investigator $145,338.68 81
PY2021 Principal investigator $14,588.05 4
PY2020 Principal investigator $129,452.46 74
PY2019 Principal investigator $432,130.59 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 12/29/2023 Non-covered Recipient Entity
Clinical Innovations Inc/ CenExel
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286983
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $100.00 12/19/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1035799839
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,530.67 12/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1035799631
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,719.02 12/08/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1035799607
Principal investigator 1 ITI, Inc. $6,093.00 12/07/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042731283
Principal investigator 1 Sumitomo Pharma America, Inc. $0.75 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286795
Principal investigator 1 Sumitomo Pharma America, Inc. $3.00 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286801
Principal investigator 1 Sumitomo Pharma America, Inc. $3.00 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286807
Principal investigator 1 Sumitomo Pharma America, Inc. $5.25 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286813
Principal investigator 1 Sumitomo Pharma America, Inc. $6.60 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286821
Principal investigator 1 Sumitomo Pharma America, Inc. $7.00 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286827
Principal investigator 1 Sumitomo Pharma America, Inc. $7.50 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286833
Principal investigator 1 Sumitomo Pharma America, Inc. $7.50 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286839
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286845
Principal investigator 1 Sumitomo Pharma America, Inc. $8.25 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286851
Principal investigator 1 Sumitomo Pharma America, Inc. $9.30 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286857
Principal investigator 1 Sumitomo Pharma America, Inc. $11.06 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286863
Principal investigator 1 Sumitomo Pharma America, Inc. $12.60 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286869
Principal investigator 1 Sumitomo Pharma America, Inc. $15.65 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286875
Principal investigator 1 Sumitomo Pharma America, Inc. $15.80 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286881
Principal investigator 1 Sumitomo Pharma America, Inc. $32.55 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286887
Principal investigator 1 Sumitomo Pharma America, Inc. $34.76 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286893
Principal investigator 1 Sumitomo Pharma America, Inc. $37.13 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286899
Principal investigator 1 Sumitomo Pharma America, Inc. $37.80 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286905
Principal investigator 1 Sumitomo Pharma America, Inc. $42.00 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286913
Principal investigator 1 Sumitomo Pharma America, Inc. $46.50 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286919
Principal investigator 1 Sumitomo Pharma America, Inc. $46.75 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286925
Principal investigator 1 Sumitomo Pharma America, Inc. $78.08 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286931
Principal investigator 1 Sumitomo Pharma America, Inc. $84.60 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286937
Principal investigator 1 Sumitomo Pharma America, Inc. $187.00 12/04/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286943
Principal investigator 1 Sumitomo Pharma America, Inc. $4,215.60 12/04/2023 Non-covered Recipient Entity
Clinical Innovations Inc.
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286989
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 11/30/2023 Non-covered Recipient Entity
Clinical Innovations Inc/ CenExel
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286977
Principal investigator 1 ITI, Inc. $659.10 11/24/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042730479
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,853.44 11/17/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1035799643
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $50,270.76 11/17/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1035799733
Principal investigator 1 ITI, Inc. $5,553.32 11/09/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042729481
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 10/31/2023 Non-covered Recipient Entity
Clinical Innovations Inc/ CenExel
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286971
Principal investigator 1 Sumitomo Pharma America, Inc. $1,500.00 10/18/2023 Non-covered Recipient Entity
Clinical Innovations Inc.
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030281375
Principal investigator 1 Sumitomo Pharma America, Inc. $2,000.00 10/18/2023 Non-covered Recipient Entity
Clinical Innovations Inc.
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030281381
Principal investigator 1 Sumitomo Pharma America, Inc. $2,000.00 10/18/2023 Non-covered Recipient Entity
Clinical Innovations Inc.
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030281387
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,446.20 10/17/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1035799657
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,171.63 10/10/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1035799621
Principal investigator 1 ITI, Inc. $1,769.33 10/04/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042725841
Principal investigator 1 Sumitomo Pharma America, Inc. $488.00 10/04/2023 Non-covered Recipient Entity
Clinical Innovations Inc.
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030281363
Principal investigator 1 Sumitomo Pharma America, Inc. $750.00 10/04/2023 Non-covered Recipient Entity
Clinical Innovations Inc.
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030281369
Principal investigator 1 Sumitomo Pharma America, Inc. $0.93 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286657
Principal investigator 1 Sumitomo Pharma America, Inc. $2.16 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286663
Principal investigator 1 Sumitomo Pharma America, Inc. $5.52 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286671
Principal investigator 1 Sumitomo Pharma America, Inc. $6.00 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286677
Principal investigator 1 Sumitomo Pharma America, Inc. $6.00 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286683
Principal investigator 1 Sumitomo Pharma America, Inc. $6.51 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286689
Principal investigator 1 Sumitomo Pharma America, Inc. $6.80 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286695
Principal investigator 1 Sumitomo Pharma America, Inc. $8.80 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286701
Principal investigator 1 Sumitomo Pharma America, Inc. $9.30 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286707
Principal investigator 1 Sumitomo Pharma America, Inc. $10.23 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286715
Principal investigator 1 Sumitomo Pharma America, Inc. $16.40 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286721
Principal investigator 1 Sumitomo Pharma America, Inc. $28.95 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286727
Principal investigator 1 Sumitomo Pharma America, Inc. $28.95 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286733
Principal investigator 1 Sumitomo Pharma America, Inc. $62.20 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286739
Principal investigator 1 Sumitomo Pharma America, Inc. $66.00 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286745
Principal investigator 1 Sumitomo Pharma America, Inc. $132.00 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286751
Principal investigator 1 Sumitomo Pharma America, Inc. $155.50 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286757
Principal investigator 1 Sumitomo Pharma America, Inc. $165.00 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286765
Principal investigator 1 Sumitomo Pharma America, Inc. $168.48 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286771
Principal investigator 1 Sumitomo Pharma America, Inc. $264.35 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286777
Principal investigator 1 Sumitomo Pharma America, Inc. $311.00 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286783
Principal investigator 1 Sumitomo Pharma America, Inc. $421.20 10/03/2023 Non-covered Recipient Entity
CITrials
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286789
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $317.42 10/03/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1035799567
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,019.60 10/03/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1035799581
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 09/29/2023 Non-covered Recipient Entity
Clinical Innovations Inc/ CenExel
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286967
Principal investigator 1 Sumitomo Pharma America, Inc. $40.00 09/06/2023 Non-covered Recipient Entity
Clinical Innovations Inc.
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030281345
Principal investigator 1 Sumitomo Pharma America, Inc. $625.00 09/06/2023 Non-covered Recipient Entity
Clinical Innovations Inc.
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030281351
Principal investigator 1 Sumitomo Pharma America, Inc. $750.00 09/06/2023 Non-covered Recipient Entity
Clinical Innovations Inc.
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030281357
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 08/31/2023 Non-covered Recipient Entity
Clinical Innovations Inc/ CenExel
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286961
Principal investigator 1 ITI, Inc. $6,106.99 08/30/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042724703
Principal investigator 1 Sumitomo Pharma America, Inc. $95.01 08/17/2023 Non-covered Recipient Entity
Clinical Innovations Inc/ CenExel
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286949
Principal investigator 1 Sumitomo Pharma America, Inc. $221.69 08/17/2023 Non-covered Recipient Entity
Clinical Innovations Inc/ CenExel
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication No dispute reported 06/30/2026 1030286955
Principal investigator 1 ITI, Inc. $8,039.46 08/03/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042723597
Principal investigator 1 ITI, Inc. $863.20 07/19/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042722713
Principal investigator 1 ITI, Inc. $2,367.45 05/03/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042718763
Principal investigator 1 ITI, Inc. $6,791.98 02/01/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042715611